---
document_datetime: 2023-09-21 18:17:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/clopidogrelacetylsalicylic-acid-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: clopidogrelacetylsalicylic-acid-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.2790898
conversion_datetime: 2025-12-15 21:19:39.882485
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Clopidogrel/Acetylsalicylic acid Teva

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                      | Opinion/ Notification 1 issued on Commission Decision Issued 2 / amended on product no   | Product Information affected 3   |
|----------------------|----------------------------------------------------------------------------|------------------------------------------------------------------------------------------|----------------------------------|
| IA/0002              | A.7 - Administrative change - Deletion of manufacturing sites              | 15/03/2016                                                                               | Annex II and PL                  |
| IAIN/0001            | A.1 - Administrative change - Change in the name and/or address of the MAH | 11/02/2016                                                                               | SmPC, Labelling and PL           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

Medicinal product no longer authorised